Ryvu Therapeutics to receive from Menarini Group a development milestone based on an amended global License Agreement
TitleFile
Current Report ESPI 40/2021
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy